Metabolism of Selegiline [(-)-Deprenyl)]

dc.contributor.author	Kalász, Huba
dc.contributor.author	Magyar, Kálmán
dc.contributor.author	Szőke, Éva
dc.contributor.author	Adeghate, Ernest Akingunola
dc.contributor.author	Adem, A
dc.contributor.author	Tekes, Kornélia
dc.date.accessioned	2016-03-30T09:41:57Z
dc.date.available	2016-03-30T09:41:57Z
dc.date.issued	2014
dc.identifier	84899798478
dc.identifier.citation	pagination=1522-1530; journalVolume=21; journalIssueNumber=13; journalTitle=CURRENT MEDICINAL CHEMISTRY;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/3027
dc.identifier.uri	doi:10.2174/0929867321666131218094352
dc.description.abstract	Selegiline [(-)-deprenyl] is used to treat patients with Parkinson's disease. Nevertheless, in much higher doses it has beneficial effects in depression, and dementia of the aged patients. Selegiline undergoes a complex metabolic pathway. Its major metabolites include desmethylselegiline, (-)-methamphetamine and (-)-amphetamine, selegiline-N-oxide and formaldehyde as a small metabolic fragment in animal experiments. In addition, more than 40 minor metabolites of selegiline have also been either detected or proposed by investigators and researchers. This review analyses the pharmacological activity, generation pathway and the detection method of the major metabolites of selegiline.
dc.relation.ispartof	urn:issn:0929-8673
dc.title	Metabolism of Selegiline [(-)-Deprenyl)]
dc.type	Journal Article
dc.date.updated	2016-01-25T09:22:59Z
dc.language.rfc3066	en
dc.identifier.mtmt	2483176
dc.identifier.wos	000333425700004
dc.identifier.pubmed	24350849
dc.contributor.department	SE/GYTK/Farmakognózia Intézet
dc.contributor.department	SE/GYTK/Gyógyszerhatástani Intézet
dc.contributor.institution	Semmelweis Egyetem